Our multimodal imaging services combine MRI, CT, PET, and X-ray technologies to deliver comprehensive visualization of therapeutic biodistribution, tissue response, and structural or functional remodeling in preclinical models. MRI offers unparalleled soft tissue contrast, enabling functional mapping of organ systems, vascular dynamics, and musculoskeletal structures, while CT provides high-resolution anatomical imaging to assess skeletal remodeling, device integration, and structural pathology. PET enables quantification of tracer-labeled therapeutics, including biodistribution, receptor occupancy, and metabolic activity, while X-ray supports rapid and cost-effective monitoring of skeletal or implant-related changes.

 

These imaging modalities are deployed longitudinally, allowing sponsors to track therapeutic impact and durability across multiple study phases without sacrificing data continuity. Integration with histological endpoints, molecular biomarkers, and pharmacokinetic sampling creates multiparametric datasets that provide mechanistic and translational insights with strong regulatory acceptance. Imaging outputs are processed using advanced analysis pipelines, ensuring consistency and precision across studies. By combining multiple imaging modalities with validated protocols and regulatory alignment, we deliver data packages that not only reduce translational uncertainty but also accelerate decision-making and clinical progression.